CureVac Shareholders Approve Merger with BioNTech

CureVac NL0015436031

CureVac's journey as an independent biotech firm is concluding following a definitive shareholder decision. Investors have overwhelmingly supported the company's integration into competitor BioNTech, setting the stage for the final merger steps. This development raises important considerations for shareholders regarding portfolio implications and critical deadlines.

The outcome of the extraordinary general meeting left no uncertainty about CureVac's future direction. An overwhelming 99.16 percent of cast votes approved BioNTech's public exchange offer, removing the final significant obstacle to the planned merger.

This decisive shareholder endorsement finalizes the strategic realignment, paving the way for the legal merger and incorporation under the Mainz-based company's umbrella. For investors, this virtually eliminates the risk of the transaction failing to proceed.

Critical Timelines for Shareholders

With shareholder approval secured, attention now turns to the technical implementation of the share conversion. Remaining investors must act promptly to exchange their holdings for BioNTech securities, noting that banking deadlines often precede official cutoff dates:

• Exchange Ratio: Shareholders will receive 0.05363 BioNTech shares (ADS) for each CureVac share they hold.
• Recommended Deadline: Due to processing requirements, investors should submit their shares by December 2, 2025, at 6:00 PM US Eastern Time.
• Formal Closing: The offer officially concludes on December 3, 2025.

Market Implications and Future Outlook

The market has largely priced in the transaction's certainty. CureVac's stock, currently trading at 4.66 euros, no longer functions as an independent security but rather tracks BioNTech's price movement in line with the fixed exchange ratio.

The impending delisting marks the end of the stock's historical volatility. Though the equity has gained approximately 38 percent since the beginning of the year, it will soon be replaced by investment exposure to BioNTech's more diversified portfolio.

Conclusion: The acquisition is technically virtually complete. Through this integration, mRNA pipeline assets and intellectual property will transfer to Mainz. Investors must now monitor deadlines closely and execute the share exchange before the final curtain falls on CureVac's independent listing.